ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatocellular carcinoma"

  • 2020 American Transplant Congress

    Early Recurrence Of Hepatocellular Carcinoma Following Transplantation: Risk Score From A Multi-institutional Study Of > 3000 Patients

    P. Tabrizian1, M. Holzner2, V. Agopian3, R. Busuttil3, G. Sapisochin4, N. Mehta5, F. Yao5, J. Roberts6, S. Florman1, M. E. Schwartz1, T. Ivanics7, J. Emond8, B. Samstein9, R. Brown, MD, MPH9, M. Najjar10, W. Chapman11, M. Doyle11, K. Halazun9

    1Transplant, Mount Sinai Medical Center, New York, NY, 2Surgery, Georgetown University Hospital, Washington DC, MD, 3Transplant, David Geffen School of Medicine at UCLA, Los Angeles, CA, 4Transplant, Univeristy of Toronto, Toronto, ON, Canada, 5Transplant, UCSF, San Francisco, CA, 6Transplantation, UCSF, San Francisco, CA, 7Transplant, University of Toronto, Toronto, ON, Canada, 8Transplant, Columbia University Medical Center, New York, NY, 9Transplant, Weill Cornell Medical Center, New York, NY, 10Transplant, Columbia Medical Center, New York, NY, 11Transplant, Washington University School of Medicine, St Louis, MO

    *Purpose: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) carries a poor prognosis. We aimed to develop a risk score for early HCC…
  • 2020 American Transplant Congress

    Performance of the Retreat Score in Predicting Post-Transplant Hepatocellular Carcinoma Recurrence at a Large Academic Center

    N. Mahmud, N. Philips, S. Ekpanyapong, S. Prenner, M. Levine, R. Reddy, M. Hoteit

    Hospital of the University of Pennsylvania, Philadelphia, PA

    *Purpose: Post-transplant hepatocellular carcinoma recurrence (R-HCC) results in poor outcomes. The RETREAT score was recently derived to predict HCC recurrence, incorporating pre-transplant alpha fetoprotein and…
  • 2020 American Transplant Congress

    The Oncological Optimal Tacrolimus Target Level after Liver Transplant for Hepatocellular Carcinoma

    K. Sasaki1, J. McVey1, D. Firl2, Y. Inaba3, C. D. Kwon1, K. Hashimoto1, F. Aucejo1

    1The Cleveland Clinic, Cleveland, OH, 2Duke University, Durham, NC, 3Chiba University, Chiba, Japan

    *Purpose: The recurrence rate after liver transplant (LT) for hepatocellular carcinoma (HCC) is high as 15-20% nevertheless of complete removal of tumor and carcinogenic liver.…
  • 2020 American Transplant Congress

    Multiple Downstaging Episodes for Hepatocellular Carcinoma Prior to Liver Transplant Increases Risk of Post-Transplant HCC Recurrence

    K. Mishra, M. Siddiqui, A. Farris, R. Salgia

    Henry Ford Hospital, Detroit, MI

    *Purpose: Early-stage Hepatocellular Carcinoma (HCC) is best managed with liver transplantation (LT). Several studies have shown that patients meeting Milan or successfully downstaged to meet…
  • 2020 American Transplant Congress

    National Experience with Living Donor Liver Transplant for Hepatocellular Carcinoma

    J. Silverstein1, F. Yao1, J. D. Grab2, H. Braun2, J. Roberts2, J. Dodge2, N. Mehta1

    1Dept of Medicine, UCSF, San Francisco, CA, 2Dept of Surgery, UCSF, San Francisco, CA

    *Purpose: LDLT is an attractive option to decrease both wait time and risk of waitlist dropout in HCC. This study aimed to evaluate temporal and…
  • 2020 American Transplant Congress

    HCC Liver Transplantation Waitlist Dropout Rates before and after the Mandated Six-Month Wait-Time

    M. LaVere1, K. Robichaux2, J. Buggs3, E. Rogers3, S. Nyce4, A. Kumar1, J. Sokolich3

    1Morsani College of Medicine, University of South Florida, Tampa, FL, 2Honors College, University of South Florida, Tampa, FL, 3Transplant Surgery, Tampa General Hospital, Tampa, FL, 4University of Tampa, Tampa, FL

    *Purpose: Studies have shown significant improvement in hepatocellular carcinoma (HCC) recurrence rates following the UNOS implementation of a six-month wait period. However, few have examined…
  • 2020 American Transplant Congress

    Comparing Post-Transplant Outcomes in Living and Deceased Donor Liver Transplantation for Patients with Hepatocellular Carcinoma: An Analysis of UNOS Registry

    T. Kitajima1, D. Moonka2, S. Yeddula1, M. Rizzari1, K. Collins1, A. Yoshida1, M. S. Abouljoud1, S. Nagai1

    1Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, 2Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI

    *Purpose: Because of possible short waiting time, living donor liver transplantation (LDLT) for HCC may provide survival benefit compared to deceased donor LT (DDLT). This…
  • 2020 American Transplant Congress

    Living Donor Liver Transplantation Should Be Considered Cautiously in Recurrent Hepatocellular Carcinoma within the Milan Criteria after Curative Liver Resection

    J. Kim1, N. Yi2, G. Choi1, C. D. Kwon3, K. Lee2, K. Suh2, J. Joh1

    1Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, 2Division of HBP Surgery, Department of Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of, 3Department of Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH

    *Purpose: Insufficient data are available about patient survival following different treatments for recurrent hepatocellular carcinoma (HCC) after primary hepatectomy. We retrospectively evaluated the effects of…
  • 2020 American Transplant Congress

    Hepatocellular Carcinoma Recurrence after Severe Acute Cellular Rejection

    M. Najjar1, O. Perez1, K. Bruestle1, A. Qian1, P. Jiang1, A. Srivastava1, Y. Saenger1, E. Verna1, E. Zheng1, A. Mathur1, A. Griesemer1, K. Halazun2, B. Samstein2, T. Kato1, J. Emond1

    1Columbia University Irving Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY

    *Purpose: The interplay between acute cellular rejection (ACR), immunosuppression and hepatocellular carcinoma (HCC) recurrence in patients who underwent liver transplantation (LT) for HCC is still…
  • 2020 American Transplant Congress

    Synergistic Anticancer Effect of Metformin in Combination with Immunosuppressant on Hepatocellular Carcinoma Cell Lines

    S. Suh1, Y. Choi1, K. Lee2

    1Surgery, Chung-Ang University, College of Medicine, Seoul, Korea, Republic of, 2Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of

    *Purpose: After liver transplantation (LT), immunosuppression is needed to avoid rejection and graft loss, however, it can stimulate hepatocellular carcinoma (HCC) recurrence and progression. Previous…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 23
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences